<p>Lazard Asset Management LLC 在最近向美国证券交易委员会提交的 13F 报告中表示，在第二季度将其在 Labcorp Holdings Inc. (NYSE:LH - 免费报告) 的持仓提高了 224.1%。该机构投资者在此期间购买了额外的 684,153 股后，持有该医疗研究公司 989,433 股股票。Lazard Asset Management LLC 在最近的报告期末持有的 Labcorp 股票约占 1.19%，价值 2.59734 亿美元。</p>
<ul>
<li>Joby 和 Archer 在阿联酋开启新的战略篇章</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。Brighton Jones LLC 在第四季度获得了约 991,000 美元的新股份。Townsquare Capital LLC 在第一季度将其在 Labcorp 的持股增加了 8.8%。Townsquare Capital LLC 现在持有 4,785 股该医疗研究公司的股票，价值 1,114,000 美元，此前在上个季度又购买了 389 股。Nuveen LLC 在第一季度获得了约 48,193,000 美元的新股份。公共部门养老金投资委员会在第一季度将其在 Labcorp 的持仓增加了 8.7%。公共部门养老金投资委员会现在持有 11,418 股该医疗研究公司的股票，价值 2,657,000 美元，此前在上个季度又购买了 913 股。最后，Resona Asset Management Co. Ltd. 在第一季度将其在 Labcorp 的持仓提高了 5.5%。Resona Asset Management Co. Ltd. 现在持有 26,981 股该医疗研究公司的股票，价值 6,268,000 美元，此前在上个季度又购买了 1,413 股。机构投资者持有该公司 95.94% 的股票。</p>
<h2>Labcorp 股票下跌 0.2%</h2>
<p>LH 周五开盘价为 264.15 美元。该公司的市值为 219 亿美元，市盈率为 25.95，市盈增长比率为 1.75，贝塔值为 0.99。该公司的 50 日移动平均线为 267.56 美元，200 日移动平均线为 266.08 美元。Labcorp Holdings Inc. 的 52 周低点为 209.38 美元，52 周高点为 293.72 美元。该公司的债务与股本比率为 0.59，流动比率为 1.55，速动比率为 1.35。</p>
<ul>
<li>Palantir 的国防合作伙伴关系推动其增长故事</li>
</ul>
<p>Labcorp (NYSE:LH - 获取免费报告) 最近在 10 月 28 日星期二发布了季度财报。该医疗研究公司报告的每股收益为 4.18 美元，超出市场共识预期的 4.13 美元，超出 0.05 美元。该公司季度收入为 35.6 亿美元，而分析师预期的收入为 35.6 亿美元。Labcorp 的净利润率为 6.21%，股本回报率为 15.85%。该公司的季度收入同比增长 8.6%。去年同期，该公司每股收益为 3.50 美元。Labcorp 已将其 2025 财年的指引设定为 16.150-16.500 每股收益。股票研究分析师预测 Labcorp Holdings Inc. 本财年将发布 16.01 每股收益。</p>
<h2>Labcorp 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 12 月 11 日星期四支付。11 月 26 日星期三的股东获得了 0.72 美元的分红。该分红的除息日为 11 月 26 日星期三。这相当于年化 2.88 美元的分红和 1.1% 的分红收益率。Labcorp 的派息比率目前为 28.29%。</p>
<h2>内部交易活动</h2>
<ul>
<li>下一代国防：3 只股票在新的全球军备竞赛中崛起</li>
</ul>
<p>在其他新闻中，首席执行官 Adam H. Schechter 于 11 月 11 日星期二出售了 5,745 股该股票。该股票以平均价格 262.75 美元出售，总交易额为 1,509,498.75 美元。交易完成后，首席执行官持有 87,574 股该公司的股票，价值约 23,010,068.50 美元。这代表其持仓减少了 6.16%。该交易在向美国证券交易委员会的法律文件中披露，相关文件可通过此链接访问。此外，董事 Richelle P. Parham 于 10 月 31 日星期五出售了 7,009 股该公司的股票。该股票以平均价格 254.28 美元出售，总价值为 1,782,248.52 美元。交易完成后，该董事直接持有 2,469 股该公司的股票，价值 627,817.32 美元。该交易使其持股减少了 73.95%。该交易的披露可在美国证券交易委员会的文件中找到。公司内部人士持有该公司 0.84% 的股票。</p>
<h2>分析师评级上调和下调</h2>
<p>LH 曾受到多份分析师报告的关注。华尔街 Zen 在 12 月 6 日星期六将 Labcorp 的评级从 “买入” 下调至 “持有”。瑞穗证券在 10 月 17 日星期五的研究报告中将 Labcorp 的目标价从 285.00 美元上调至 320.00 美元，并给予该公司 “跑赢大盘” 的评级。摩根大通在 11 月 7 日星期五的报告中将 Labcorp 的目标价从 291.00 美元上调至 317.00 美元，并给予该公司 “增持” 的评级。巴克莱在 10 月 2 日星期四的报告中将 Labcorp 的目标价从 275.00 美元上调至 290.00 美元，并给予该公司 “持平” 的评级。最后，瑞银集团在 10 月 29 日星期三的研究报告中将 Labcorp 的目标价从 325.00 美元下调至 320.00 美元，并对该公司给予 “买入” 评级。共有 11 位投资分析师对该股票给予 “买入” 评级，4 位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat 的数据，Labcorp 的平均评级为 “适度买入”，平均目标价为 299.08 美元。</p>
<p><strong>查看我们最新的 LH 研究报告</strong></p>
<h2>Labcorp 公司简介</h2>
<p>(免费报告)</p>
<p>Labcorp Holdings, Inc 从事提供医疗检测服务。该公司成立于 2024 年 4 月 16 日，总部位于北卡罗来纳州伯灵顿。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比药明康德更好的股票</li>
<li>消费品股票解析</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>股票交易术语 - 每个投资者需要知道的股票术语</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>MarketBeat 周度回顾 – 12/8 - 12/12</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

实验美控

<p>Lazard Asset Management LLC 在第二季度将其在 Labcorp Holdings Inc. 的持股增加了 224.1%，持有 989,433 股，价值 2.597 亿美元。其他投资者也调整了他们在 Labcorp 的持仓。该公司报告第三季度每股收益为 4.18 美元，超出预期，营收同比增长 8.6%。Labcorp 宣布每股季度分红为 0.72 美元。内部人士的出售包括首席执行官 Adam Schechter 和董事 Richelle Parham。分析师对 Labcorp 的评级不一，瑞穗证券提高了其目标股价</p>

<p>Lazard Asset Management LLC lifted its position in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 224.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 989,433 shares of the medical research company's stock after buying an additional 684,153 shares during the period. Lazard Asset Management LLC owned approximately 1.19% of Labcorp worth $259,734,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Lazard Asset Management LLC 在最近向美国证券交易委员会提交的 13F 报告中表示，在第二季度将其在 Labcorp Holdings Inc. (NYSE:LH - 免费报告) 的持仓提高了 224.1%。该机构投资者在此期间购买了额外的 684,153 股后，持有该医疗研究公司 989,433 股股票。Lazard Asset Management LLC 在最近的报告期末持有的 Labcorp 股票约占 1.19%，价值 2.59734 亿美元。</p>
</div><ul>
<li>Joby and Archer Forge a New Strategic Chapter in the UAE</li>
</ul>
<div class="lb-trans"><ul>
<li>Joby 和 Archer 在阿联酋开启新的战略篇章</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Brighton Jones LLC acquired a new stake in Labcorp in the 4th quarter valued at about $991,000. Townsquare Capital LLC boosted its holdings in Labcorp by 8.8% during the first quarter. Townsquare Capital LLC now owns 4,785 shares of the medical research company's stock worth $1,114,000 after buying an additional 389 shares in the last quarter. Nuveen LLC acquired a new position in Labcorp in the first quarter worth approximately $48,193,000. Public Sector Pension Investment Board grew its position in Labcorp by 8.7% in the first quarter. Public Sector Pension Investment Board now owns 11,418 shares of the medical research company's stock worth $2,657,000 after buying an additional 913 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its position in shares of Labcorp by 5.5% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 26,981 shares of the medical research company's stock valued at $6,268,000 after acquiring an additional 1,413 shares during the last quarter. Institutional investors own 95.94% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。Brighton Jones LLC 在第四季度获得了约 991,000 美元的新股份。Townsquare Capital LLC 在第一季度将其在 Labcorp 的持股增加了 8.8%。Townsquare Capital LLC 现在持有 4,785 股该医疗研究公司的股票，价值 1,114,000 美元，此前在上个季度又购买了 389 股。Nuveen LLC 在第一季度获得了约 48,193,000 美元的新股份。公共部门养老金投资委员会在第一季度将其在 Labcorp 的持仓增加了 8.7%。公共部门养老金投资委员会现在持有 11,418 股该医疗研究公司的股票，价值 2,657,000 美元，此前在上个季度又购买了 913 股。最后，Resona Asset Management Co. Ltd. 在第一季度将其在 Labcorp 的持仓提高了 5.5%。Resona Asset Management Co. Ltd. 现在持有 26,981 股该医疗研究公司的股票，价值 6,268,000 美元，此前在上个季度又购买了 1,413 股。机构投资者持有该公司 95.94% 的股票。</p>
</div><h2>Labcorp Stock Down 0.2%</h2>
<div class="lb-trans"><h2>Labcorp 股票下跌 0.2%</h2>
</div><p>LH opened at $264.15 on Friday. The company has a market capitalization of $21.90 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 1.75 and a beta of 0.99. The business has a 50-day moving average of $267.56 and a 200-day moving average of $266.08. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.35.</p>
<div class="lb-trans"><p>LH 周五开盘价为 264.15 美元。该公司的市值为 219 亿美元，市盈率为 25.95，市盈增长比率为 1.75，贝塔值为 0.99。该公司的 50 日移动平均线为 267.56 美元，200 日移动平均线为 266.08 美元。Labcorp Holdings Inc. 的 52 周低点为 209.38 美元，52 周高点为 293.72 美元。该公司的债务与股本比率为 0.59，流动比率为 1.55，速动比率为 1.35。</p>
</div><ul>
<li>Palantir’s Defense Partnerships Fuel Its Growth Story</li>
</ul>
<div class="lb-trans"><ul>
<li>Palantir 的国防合作伙伴关系推动其增长故事</li>
</ul>
</div><p>Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $4.18 earnings per share for the quarter, beating the consensus estimate of $4.13 by $0.05. The firm had revenue of $3.56 billion for the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.21% and a return on equity of 15.85%. The company's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.50 earnings per share. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS. Equities research analysts forecast that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Labcorp (NYSE:LH - 获取免费报告) 最近在 10 月 28 日星期二发布了季度财报。该医疗研究公司报告的每股收益为 4.18 美元，超出市场共识预期的 4.13 美元，超出 0.05 美元。该公司季度收入为 35.6 亿美元，而分析师预期的收入为 35.6 亿美元。Labcorp 的净利润率为 6.21%，股本回报率为 15.85%。该公司的季度收入同比增长 8.6%。去年同期，该公司每股收益为 3.50 美元。Labcorp 已将其 2025 财年的指引设定为 16.150-16.500 每股收益。股票研究分析师预测 Labcorp Holdings Inc. 本财年将发布 16.01 每股收益。</p>
</div><h2>Labcorp Announces Dividend</h2>
<div class="lb-trans"><h2>Labcorp 宣布分红</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Wednesday, November 26th were given a $0.72 dividend. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp's payout ratio is currently 28.29%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 12 月 11 日星期四支付。11 月 26 日星期三的股东获得了 0.72 美元的分红。该分红的除息日为 11 月 26 日星期三。这相当于年化 2.88 美元的分红和 1.1% 的分红收益率。Labcorp 的派息比率目前为 28.29%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><ul>
<li>Next-Gen Defense: 3 Stocks Riding the New Global Arms Race</li>
</ul>
<div class="lb-trans"><ul>
<li>下一代国防：3 只股票在新的全球军备竞赛中崛起</li>
</ul>
</div><p>In other news, CEO Adam H. Schechter sold 5,745 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $262.75, for a total transaction of $1,509,498.75. Following the transaction, the chief executive officer owned 87,574 shares of the company's stock, valued at approximately $23,010,068.50. This represents a 6.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richelle P. Parham sold 7,009 shares of the firm's stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $254.28, for a total value of $1,782,248.52. Following the completion of the transaction, the director directly owned 2,469 shares in the company, valued at $627,817.32. The trade was a 73.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.84% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Adam H. Schechter 于 11 月 11 日星期二出售了 5,745 股该股票。该股票以平均价格 262.75 美元出售，总交易额为 1,509,498.75 美元。交易完成后，首席执行官持有 87,574 股该公司的股票，价值约 23,010,068.50 美元。这代表其持仓减少了 6.16%。该交易在向美国证券交易委员会的法律文件中披露，相关文件可通过此链接访问。此外，董事 Richelle P. Parham 于 10 月 31 日星期五出售了 7,009 股该公司的股票。该股票以平均价格 254.28 美元出售，总价值为 1,782,248.52 美元。交易完成后，该董事直接持有 2,469 股该公司的股票，价值 627,817.32 美元。该交易使其持股减少了 73.95%。该交易的披露可在美国证券交易委员会的文件中找到。公司内部人士持有该公司 0.84% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>LH has been the subject of several analyst reports. Wall Street Zen downgraded Labcorp from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th. Mizuho upped their price objective on shares of Labcorp from $285.00 to $320.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, October 17th. JPMorgan Chase &amp; Co. boosted their price target on shares of Labcorp from $291.00 to $317.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, November 7th. Barclays lifted their price target on Labcorp from $275.00 to $290.00 and gave the company an &#34;equal weight&#34; rating in a report on Thursday, October 2nd. Finally, UBS Group reduced their price objective on Labcorp from $325.00 to $320.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, October 29th. Eleven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Labcorp has an average rating of &#34;Moderate Buy&#34; and an average price target of $299.08.</p>
<div class="lb-trans"><p>LH 曾受到多份分析师报告的关注。华尔街 Zen 在 12 月 6 日星期六将 Labcorp 的评级从 “买入” 下调至 “持有”。瑞穗证券在 10 月 17 日星期五的研究报告中将 Labcorp 的目标价从 285.00 美元上调至 320.00 美元，并给予该公司 “跑赢大盘” 的评级。摩根大通在 11 月 7 日星期五的报告中将 Labcorp 的目标价从 291.00 美元上调至 317.00 美元，并给予该公司 “增持” 的评级。巴克莱在 10 月 2 日星期四的报告中将 Labcorp 的目标价从 275.00 美元上调至 290.00 美元，并给予该公司 “持平” 的评级。最后，瑞银集团在 10 月 29 日星期三的研究报告中将 Labcorp 的目标价从 325.00 美元下调至 320.00 美元，并对该公司给予 “买入” 评级。共有 11 位投资分析师对该股票给予 “买入” 评级，4 位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat 的数据，Labcorp 的平均评级为 “适度买入”，平均目标价为 299.08 美元。</p>
</div><p><strong>View Our Latest Research Report on LH</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LH 研究报告</strong></p>
</div><h2>Labcorp Company Profile</h2>
<div class="lb-trans"><h2>Labcorp 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.</p>
<div class="lb-trans"><p>Labcorp Holdings, Inc 从事提供医疗检测服务。该公司成立于 2024 年 4 月 16 日，总部位于北卡罗来纳州伯灵顿。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Labcorp</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>MarketBeat Week in Review – 12/8 - 12/12</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比药明康德更好的股票</li>
<li>消费品股票解析</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>股票交易术语 - 每个投资者需要知道的股票术语</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>MarketBeat 周度回顾 – 12/8 - 12/12</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Labcorp Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在药明康德吗？</h2>
</div><p>Before you consider Labcorp, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
</div><p>While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

实验美控控股公司 $LH 的股票被 Lazard 资产管理公司购入